Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

NCT00567996 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1002

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Indacaterol 150 μg
DRUG: Salmeterol 50 μg
DRUG: Placebo to Indacaterol
DRUG: Placebo to Salmeterol

Sponsor

Novartis